Tiagabine

Drug Profile

Tiagabine

Alternative Names: A-70569; CEP-6671; Gabitril; NO-050328; NO-328; Tiagabine hydrochloride

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer Cephalon; Novo Nordisk; Teva Pharmaceutical Industries
  • Class Antiepileptic drugs; Nipecotic acids; Small molecules
  • Mechanism of Action GABA uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Anxiety disorders; Insomnia; Neuropathic pain

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 14 Oct 2011 Cephalon has been acquired by Teva Pharmaceutical Industries
  • 15 Oct 2010 The US FDA approves a risk evaluation and mitigation strategy for tiagabine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top